Skip to main content
Oral triple combo benefits patients with advanced multiple myeloma

A study of 77 patients treated in seven centers in Hungary indicated that treatment with the oral triple combination regimen of Ninlaro, or ixazomib, Revlimid, or lenalidomide, and dexamethasone extended time to disease progression or death in patients with multiple myeloma who had received prior treatment. The data were reported in the journal Pathology & Oncology Research.

Full Story: